ANTX
Price
$1.32
Change
-$0.02 (-1.49%)
Updated
Dec 18, 04:59 PM (EDT)
99 days until earnings call
CERO
Price
$0.06
Change
-$0.00 (-0.00%)
Updated
Dec 18, 04:59 PM (EDT)
Ad is loading...

ANTX vs CERO

Header iconANTX vs CERO Comparison
Open Charts ANTX vs CEROBanner chart's image
AN2 Therapeutics
Price$1.32
Change-$0.02 (-1.49%)
Volume$669
CapitalizationN/A
CERo Therapeutics Holdings
Price$0.06
Change-$0.00 (-0.00%)
Volume$216.74K
CapitalizationN/A
ANTX vs CERO Comparison Chart
Loading...
ANTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CERO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ANTX vs. CERO commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANTX is a Buy and CERO is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (ANTX: $1.34 vs. CERO: $0.06)
Brand notoriety: ANTX and CERO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANTX: 24% vs. CERO: 281%
Market capitalization -- ANTX: $40.04M vs. CERO: $9.18M
ANTX [@Biotechnology] is valued at $40.04M. CERO’s [@Biotechnology] market capitalization is $9.18M. The market cap for tickers in the [@Biotechnology] industry ranges from $482.1B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANTX’s FA Score shows that 1 FA rating(s) are green whileCERO’s FA Score has 1 green FA rating(s).

  • ANTX’s FA Score: 1 green, 4 red.
  • CERO’s FA Score: 1 green, 4 red.
According to our system of comparison, ANTX is a better buy in the long-term than CERO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANTX’s TA Score shows that 4 TA indicator(s) are bullish while CERO’s TA Score has 3 bullish TA indicator(s).

  • ANTX’s TA Score: 4 bullish, 5 bearish.
  • CERO’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ANTX is a better buy in the short-term than CERO.

Price Growth

ANTX (@Biotechnology) experienced а -11.26% price change this week, while CERO (@Biotechnology) price change was -31.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.92%, and the average quarterly price growth was +0.65%.

Reported Earning Dates

ANTX is expected to report earnings on Mar 27, 2025.

CERO is expected to report earnings on Mar 24, 2023.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ANTX($40M) has a higher market cap than CERO($9.18M). ANTX YTD gains are higher at: -93.460 vs. CERO (-99.445). ANTX has more cash in the bank: 93.4M vs. CERO (3.65M).
ANTXCEROANTX / CERO
Capitalization40M9.18M436%
EBITDA-64.76MN/A-
Gain YTD-93.460-99.44594%
P/E RatioN/AN/A-
Revenue0N/A-
Total Cash93.4M3.65M2,561%
Total DebtN/A2.15M-
TECHNICAL ANALYSIS
Technical Analysis
ANTXCERO
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
43%
Momentum
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
31%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
17%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
51%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
68%
Advances
ODDS (%)
Bullish Trend 8 days ago
87%
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 3 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
60%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
ANTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CERO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CEIZX13.55N/A
N/A
Manning & Napier Callodine Equity Inc Z
ETNHX33.97-0.14
-0.41%
Eventide Healthcare & Life Sciences N
ARTIX27.61-0.13
-0.47%
Artisan International Investor
IBSSX24.05-0.24
-0.99%
VY® Baron Growth S
FHUMX16.93-0.23
-1.34%
Federated Hermes US SMID Institutional

ANTX and

Correlation & Price change

A.I.dvisor tells us that ANTX and NKTX have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ANTX and NKTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANTX
1D Price
Change %
ANTX100%
-0.74%
NKTX - ANTX
26%
Poorly correlated
-1.73%
CSLLY - ANTX
26%
Poorly correlated
+0.84%
RANI - ANTX
25%
Poorly correlated
-8.18%
CERO - ANTX
24%
Poorly correlated
+19.80%
SCPX - ANTX
24%
Poorly correlated
-1.82%
More

CERO and

Correlation & Price change

A.I.dvisor tells us that CERO and BRTX have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CERO and BRTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CERO
1D Price
Change %
CERO100%
+19.80%
BRTX - CERO
30%
Poorly correlated
+6.16%
AGEN - CERO
25%
Poorly correlated
+4.42%
GOVX - CERO
25%
Poorly correlated
-0.87%
ANTX - CERO
24%
Poorly correlated
-0.74%
CELC - CERO
23%
Poorly correlated
N/A
More